Prostate cancer
FL-020-001
A First-in-human, Phase 1 Dose Escalation and Expansion Study evaluating the Safety, Tolerability and Anti-tumor Activity of [ 225Ac]Ac-FL-020, an anti-PSMA Radioconjugate (RDC), in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Trial overview
Clinical Area
Theranostics
Disease / Condition
Prostate
Study Phase
I
Trial Identifiers
GenesisCare Location(s)
Principal Investigator(s)